|
Aegis Therapeutics Related
 |
"Oral delivery of octreotide acetate in Intravail® improves uptake, half-life, and bioavailability over subcutaneous administration in male Swiss Webster mice", E.T. Maggio, P. Grasso, Regulatory Peptides (2011) 167: 233–238 |
|
"n-Dodecyl-β-D-Maltoside Inhibits Aggregation of Human Interferon-β-1b and Reduces Its Immunogenicity", Rifkin RA, Maggio ET, Dike S, Kerr DA and Levy M, J Neuroimmune Pharmacol (2010) 6:1, 158-162 |
|
Use of excipients to control aggregation in peptide and protein formulations.", Maggio ET, J. Excipients and Food Chem. (2010) 1(2) pp 40-49. |
|
"Oral delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male C57BL/6J wild-type and ob/ob mice: effects on energy balance, glycaemic control and serum osteocalcin levels", Novakovic ZM, Leinung MC, Lee DW & Grasso P, Diabetes, Obesity and Metabolism (2010) abstract only - Full PDF available online. |
|
"Highly Bioavailable Nasal Calcitonin - Potential for Expanded Use in Analgesia". Maggio ET, Meezan E, Ghambeer DKS and Pillion DJ, Drug Delivery Technology (2010) 10(1): 58-63. |
|
"Oral delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male Swiss Webster mice: A study comparing the pharmacokinetics of oral delivery to intraperitoneal, subcutaneous, intramuscular, and intranasal administration". Lee DW, Leinung MC and Grasso P, Regulatory Peptides 160 (2010) 160: 129–132 |
|
"Noninvasive Delivery Offers Opportunities For Large And Small Pharma" in Life Science Leader –January 2010 issue, p.45 |
 |
“Intranasal (IN) Pharmacokinetics (PK) and Bioavailability of ZT-031, a Novel Parathyroid Hormone (PTH) Analog”, Eddy P, Krause D, Merutka G and MacDonald B, Presented at the ASBMR 30th Annual Meeting Sept. 16, 2009. |
|
“In Vitro Nasal Spray Characterization”, Julie D. Suman, Inhalation (2009) 3(3):14-17. |
|
“Selecting a nasal spray pump”, Degenhard Marx, Inhalation (2009) 3(3):18-21. |
|
|
“Oral delivery of mouse [D-Leu-4]-OB3, a synthetic peptide amide with leptin-like activity, in male C57BL/6J wild type and ob/ob mice: effects on energy balance, glycemic control, and serum osteocalcin levels” (Abstract), Novakovic ZM, Leinung MC, Lee DW, and Grasso P, Diabetes, Obesity and Metabolism (2009), Published Online: 25 Nov 2009. |
|
“Intranasal administration of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems” (Abstract), Novakovic ZM, Leinung MC, Lee DW, and Grasso P, Regulatory Peptides (2009) 154:107-111. |
|
“Novel Excipients Prevent Aggregation in Manufacturing and Formulation of Protein and Peptide Therapeutics” in BioProcess International – November 2008 |
|
“Non-Invasive Peptide Delivery, Reformulation, and the Pharma Finance Environment” in PharmaVentures’ Drug Delivery Report – Winter 2007/2008 |
|
“Intravail®: Highly Effective Intranasal Delivery Of Peptide And Protein Drugs” – Expert Opin. Drug Deliv. (2006) 3(4):529-539 |
|
"A Renaissance in Peptide Therapeutics is Underway" in PharmaVentures’ Drug Delivery Report – Spring/Summer 2006 |
|
Recent Developments in Intranasal Drug Delivery Technology are Creating New Vistas for Peptide and Protein Therapeutics” recently appearing in PharmaVentures’ “Drug Delivery Companies Report – Spring/Summer 2005 |
Industry Information Sources
|
|
